Cas:17177-98-9 2,4-ditert-butyl-1-methoxybenzene manufacturer & supplier

We serve Chemical Name:2,4-ditert-butyl-1-methoxybenzene CAS:17177-98-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2,4-ditert-butyl-1-methoxybenzene

Chemical Name:2,4-ditert-butyl-1-methoxybenzene
CAS.NO:17177-98-9
Synonyms:2,4-di-t-butylanisole;2,4-Di-tert-butyl-anisol;2,4-di-tert-butyl-anisole;2,4-di-t-butylmethoxybenzene;2,4-Di-tert-butyl-1-methoxybenzene
Molecular Formula:C15H24O
Molecular Weight:220.35000
HS Code:2909309090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:9.23000
Exact Mass:220.18300
LogP:4.29020

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2,4-di-t-butylanisole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4-Di-tert-butyl-1-methoxybenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-Di-tert-butyl-1-methoxybenzene Use and application,2,4-di-t-butylanisole technical grade,usp/ep/jp grade.


Related News: The on-body wear is similar to that of an insulin pump. Unlike insulin pump therapy, however, the investigational system is designed such that users enter only their body weight for the iLet to initialize therapy. 2,4-ditert-butyl-1-methoxybenzene manufacturer This is how an API becomes a medicine. 2,4-ditert-butyl-1-methoxybenzene supplier The pharmaceutical industry is related to the national economy and the people’s livelihood. The entire upstream and downstream areas involve all aspects of the national economy. Our government has a long-term direct or indirect policy preference for this. 2,4-ditert-butyl-1-methoxybenzene vendor This is how an API becomes a medicine. 2,4-ditert-butyl-1-methoxybenzene factory In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.